|1.||Miossec, Patrick: 7 articles (02/2015 - 06/2012)|
|2.||Rosenstock, Julio: 6 articles (07/2015 - 09/2013)|
|3.||Aronson, Ronnie: 6 articles (09/2014 - 09/2013)|
|4.||Niemoeller, E: 5 articles (11/2015 - 10/2012)|
|5.||Niemoeller, Elisabeth: 5 articles (11/2015 - 09/2013)|
|6.||Raccah, Denis: 5 articles (02/2015 - 06/2012)|
|7.||Ping, Lin: 4 articles (12/2015 - 09/2013)|
|8.||Riddle, Matthew C: 4 articles (12/2015 - 09/2013)|
|9.||Knop, Filip K: 4 articles (10/2014 - 08/2009)|
|10.||Christensen, Mikkel: 4 articles (10/2014 - 08/2009)|
|1.||Body Weight (Weight, Body)
02/01/2014 - "Lixisenatide one- or two-step dose-increase regimens significantly improved glycaemic control and decreased body weight over 24 weeks and during a long-term extension period without increasing hypoglycaemia. "
11/01/2014 - "Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes."
11/01/2015 - "Body weight was reduced with lixisenatide but with no significant difference vs. placebo. "
05/01/2014 - "Lixisenatide significantly lowered FPG and body weight versus placebo. "
11/01/2013 - "There was a small decrease in body weight with lixisenatide once daily and a small increase with placebo, with no statistically significant difference between the two groups. "
|2.||Weight Loss (Weight Reduction)
05/01/2014 - "Once-daily lixisenatide significantly improved glycemic control, with a pronounced postprandial effect, without significant increase in symptomatic/severe hypoglycemia risk and with weight loss over 24 weeks."
11/01/2014 - "There was no difference in weight loss versus placebo, with a modest reduction in body weight reported for both groups (lixisenatide: -1.50 kg, placebo: -1.24 kg; p = 0.296). "
08/01/2009 - "In two phase II clinical trials, lixisenatide improved glucose tolerance, resulted in weight loss and lowered HbA1C, thereby causing significantly more patients to achieve target HbA1C levels compared with placebo. "
01/01/2014 - "Lixisenatide treatment was associated with a lower risk of hypoglycaemia and a greater weight loss compared with NPH-insulin. "
10/01/2013 - "Both agents induced weight loss (from 94.5 to 91.7 kg and from 96.7 to 92.9 kg with lixisenatide and exenatide, respectively). "
|3.||Type 2 Diabetes Mellitus (MODY)
11/01/2014 - "In Asian patients with type 2 diabetes mellitus insufficiently controlled on metformin ± sulfonylurea, lixisenatide significantly improved glycaemic control and was well tolerated during the 24-week study."
11/01/2015 - "This 76-week, open-label, parallel-group study assessed the long-term safety of once-daily lixisenatide monotherapy in Japanese patients with type 2 diabetes mellitus. "
09/01/2014 - "The aim of this study is to explore whether administration timing affects glycaemic control by lixisenatide once-daily in type 2 diabetes mellitus (T2DM). "
11/01/2015 - "Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan."
02/01/2015 - "These data suggest that lixisenatide is effective and well tolerated in elderly and very elderly patients with type 2 diabetes mellitus."
|4.||Hypoglycemia (Reactive Hypoglycemia)
11/01/2015 - "The incidence of symptomatic hypoglycemia was 39.0 vs. 13.5% in patients receiving sulfonylureas and 32.3 vs. 22.9% in those not receiving sulfonylureas, for lixisenatide and placebo, respectively. "
03/01/2015 - "The incidence of symptomatic hypoglycemia was higher with lixisenatide vs the placebo (17.1 and 9.8%, respectively), with no cases of severe symptomatic hypoglycemia in either group. "
08/01/2014 - "Symptomatic hypoglycemia was experienced by 8.55% and 3.55% of patients in the lixisenatide plus OADs and placebo plus OADs groups, respectively (p=0.0276), although no serious hypoglycemic episodes were reported. "
05/01/2014 - "Lixisenatide did not significantly increase symptomatic hypoglycemia versus placebo (15.3% vs. 12.3%, respectively); one severe episode of hypoglycemia was reported with lixisenatide. "
09/01/2013 - "Symptomatic hypoglycemia was 28% for lixisenatide and 22% for placebo; 4 of 328 subjects (1.2%) had severe hypoglycemia with lixisenatide vs. 0 of 167 with placebo. "
11/01/2014 - "injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested. "
02/01/2014 - "We found that liraglutide, lixisenatide, and D-Ala2-GIP cross the blood-brain barrier and prevent the impairment in memory formation and synaptic plasticity, increase synapse numbers, reduce amyloid plaque load and soluble amyloid-β levels, reduce oxidative stress and the chronic inflammation response in the brain, enhance the proliferation of neuronal progenitor cells, and increase neurogenesis in the dentate gyrus. "
04/01/2014 - "In animal models of AD, GLP-1 mimetics such as exendin-4, liraglutide and lixisenatide have shown protective effects in the CNS by reducing β-amyloid plaques, preventing loss of synapses and memory impairments, and reducing oxidative stress and the chronic inflammatory response in the brain. "
|1.||Glucagon-Like Peptide 1 (GLP 1)
|8.||glargine (insulin glargine)